Amphetamine Products Available for ADHD and Narcolepsy
Amphetamine products are available in multiple immediate-release and extended-release formulations, including mixed amphetamine salts (Adderall/Adderall XR), dextroamphetamine (Dexedrine/Dexedrine Spansule), and lisdexamfetamine (Vyvanse), with various delivery systems designed to provide flexible dosing options for different patient needs. 1
Immediate-Release Amphetamine Formulations
Dextroamphetamine (Dexedrine)
- Starting dose: 5 mg once or twice daily
- Dose range: 5-30 mg/day, typically divided as twice daily dosing
- Maximum: Up to 50 mg/day 1, 2
Mixed Amphetamine Salts (Adderall)
- Generic formulation containing a 3:1 ratio of dextroamphetamine to levoamphetamine 3
- Provides rapid onset within 1.5 hours 4
- Immediate-release formulations allow for flexible twice-daily dosing
Extended-Release Amphetamine Formulations
Mixed Amphetamine Salts Extended-Release (Adderall XR)
- Starting dose: 10 mg once daily in the morning
- Titration: Increase by 5 mg weekly increments
- Maximum: Up to 50 mg/day 1
- Mechanism: Contains immediate-release pellets that release half the dose upon ingestion, with delayed-release pellets releasing the second half approximately 4 hours later 4
- Duration: Provides 12-hour coverage with rapid onset within 1.5 hours 4
- Formulation advantage: Capsules can be opened and sprinkled on soft food for patients with swallowing difficulties 2, 5
Dextroamphetamine Extended-Release (Dexedrine Spansule)
- Starting dose: 10 mg once daily in the morning
- Titration: Increase by 5 mg increments
- Maximum: Up to 50 mg/day 1
- Formulation advantage: Capsule forms can be sprinkled in food 2
Lisdexamfetamine (Vyvanse)
- Starting dose: 20-30 mg once daily in the morning
- Titration: Increase by 10 mg weekly
- Maximum: 70 mg/day 1
- Unique mechanism: Prodrug that is converted to dextroamphetamine after absorption, providing a smoother pharmacokinetic profile 1
- Duration: Once-daily extended-release formulation 5
Novel Delivery Systems
Recent formulations have expanded beyond traditional tablets and capsules to address patient-specific needs 5, 6:
- Chewable tablets: Available for patients unable to swallow pills
- Liquid formulations: Extended-release oral suspensions now available
- Orally disintegrating tablets: Provide alternative administration route
- Capsules that can be opened and sprinkled: Allow flexible administration on soft foods 2, 5
Pharmacokinetic Considerations
Key differences in absorption and duration:
- Immediate-release formulations typically reach peak plasma concentration (Tmax) in 2-3 hours 3
- Children exhibit shorter plasma half-life (
7 hours) compared to adults (10-12 hours) 3 - Body weight is a fundamental determinant of plasma concentrations, requiring weight-based dosing considerations 3
- Extended-release formulations provide dose-proportional pharmacokinetics with predictable exposure 3
Clinical Selection Algorithm
When choosing between formulations, prioritize:
Symptom coverage needs: If symptoms require all-day control (school + homework + evening activities), select extended-release formulations like Adderall XR or Vyvanse 7
Ability to swallow pills: For patients with difficulty swallowing, use chewable tablets, liquid formulations, or capsules that can be sprinkled on food 5, 6
Onset requirements: If rapid morning symptom control is critical, mixed amphetamine salts XR provides onset within 1.5 hours 4
Duration requirements: Lisdexamfetamine may provide smoother, longer duration due to its prodrug mechanism 1
Age considerations: For preschool-aged children (4-5 years), amphetamine has FDA approval but methylphenidate has stronger evidence; amphetamine should not be first-line in this age group 8
Common Pitfalls to Avoid
- Underdosing: Stimulants are frequently underdosed in clinical practice; flexible titration to higher doses within FDA-approved ranges improves both efficacy and acceptability 9
- Fixed dosing without adjustment: Flexible-dose strategies that allow adjustment based on symptom control and tolerability demonstrate better outcomes than rigid fixed-dose approaches 9
- Ignoring pharmacokinetic differences in children: Children metabolize amphetamines faster than adults, requiring appropriate dose adjustments 3
- Abrupt discontinuation: While less critical than with alpha-agonists, consider gradual taper to assess ongoing need rather than sudden cessation
Safety Monitoring
Monitor for common adverse effects: